ARTICLE | Company News
PTC acquiring CNS gene therapy play Agilis
July 20, 2018 5:50 PM UTC
PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders.
PTC will pay Agilis shareholders about $200 million up front, including $50 million in cash and about $150 million in PTC stock. Agilis shareholders are also eligible for $745 million in development and sales milestones, plus potential royalties of 2-6% for Agilis' programs for Friedreich ataxia and Angelman syndrome. ...
BCIQ Company Profiles